Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Korde

Showing results (21-30 of 125) with videos related to

Pageof 13
Sort By:
Haematologica|December 5, 2014
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trialsElisabet E Manasanch, Neha Korde, Sham Mailankody, et al.
Experimental Cell Research|May 26, 2007
Softness, strength and self-repair in intermediate filament networksOliver I Wagner, Sebastian Rammensee, Neha Korde, et al.
JAMA Oncology|November 27, 2018
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical TrialDickran Kazandjian, Neha Korde, Sham Mailankody, et al.
Nature Reviews. Clinical Oncology|January 28, 2015
Minimal residual disease in multiple myeloma: bringing the bench to the bedsideSham Mailankody, Neha Korde, Alexander M Lesokhin, et al.
Blood|July 13, 2013
MGUS prevalence in a cohort of AML patientsS Peter Wu, Rene Costello, Jonathan N Hofmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2016
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with MyelomaMattias Carlsten, Neha Korde, Ritesh Kotecha, et al.
European Journal of Haematology|October 12, 2013
Smoldering multiple myeloma: present position and potential promisesNishant Tageja, Elisabet E Manasanch, Neha Korde, et al.
American Journal of Hematology|March 15, 2024
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, et al.
Blood|July 29, 2011
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Sham Mailankody, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2017
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphismsTristan M Sissung, Cody J Peer, Neha Korde, et al.
Pageof 13

Showing results (21-30 of 125) with videos related to

Sort By:
Pageof 13
Haematologica|December 5, 2014
Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trialsElisabet E Manasanch, Neha Korde, Sham Mailankody, et al.
Experimental Cell Research|May 26, 2007
Softness, strength and self-repair in intermediate filament networksOliver I Wagner, Sebastian Rammensee, Neha Korde, et al.
JAMA Oncology|November 27, 2018
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical TrialDickran Kazandjian, Neha Korde, Sham Mailankody, et al.
Nature Reviews. Clinical Oncology|January 28, 2015
Minimal residual disease in multiple myeloma: bringing the bench to the bedsideSham Mailankody, Neha Korde, Alexander M Lesokhin, et al.
Blood|July 13, 2013
MGUS prevalence in a cohort of AML patientsS Peter Wu, Rene Costello, Jonathan N Hofmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2016
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with MyelomaMattias Carlsten, Neha Korde, Ritesh Kotecha, et al.
European Journal of Haematology|October 12, 2013
Smoldering multiple myeloma: present position and potential promisesNishant Tageja, Elisabet E Manasanch, Neha Korde, et al.
American Journal of Hematology|March 15, 2024
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, et al.
Blood|July 29, 2011
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Sham Mailankody, Ruth M Pfeiffer, Sigurdur Y Kristinsson, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2017
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphismsTristan M Sissung, Cody J Peer, Neha Korde, et al.
Pageof 13